Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Neurocrine Biosciences Inc (NBIX) vs Ryanair Holdings plc (RYAAY) Price & Performance

Neurocrine Biosciences IncTrade
Ryanair Holdings plcTrade

Price performance (Past 24H)

Key statistics

Neurocrine Biosciences Inc vs Ryanair Holdings plc — how do they compare? Neurocrine Biosciences Inc trades at $152.5 (market cap $16.46B), while Ryanair Holdings plc trades at $60.03 (market cap $29.63B). The key difference: Ryanair Holdings plc is the larger of the two by market cap, and Ryanair Holdings plc pays a 1.51% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.

NBIXRYAAY
Market Cap
$16.46B$29.63B
Sector
HealthIndustrials
52-Week High
$185.50$73.82
52-Week Low
$123.10$53.24
Enterprise Value
$16.48B$26.61B
Dividend Yield
1.51%

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

Read more on NBIX

About Ryanair Holdings plc

Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.

Read more on RYAAY